Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024)

Historic Current Deferred Revenue for Relay Therapeutics (RLAY) over the last 4 years, with Q4 2024 value amounting to $7.7 million.

  • Relay Therapeutics' Current Deferred Revenue changed N/A to $7.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.7 million, marking a year-over-year change of. This contributed to the annual value of $7.7 million for FY2024, which is N/A changed from last year.
  • As of Q4 2024, Relay Therapeutics' Current Deferred Revenue stood at $7.7 million.
  • In the past 5 years, Relay Therapeutics' Current Deferred Revenue registered a high of $7.7 million during Q4 2024, and its lowest value of $15000.0 during Q2 2023.
  • In the last 4 years, Relay Therapeutics' Current Deferred Revenue had a median value of $207000.0 in 2021 and averaged $1.1 million.
  • As far as peak fluctuations go, Relay Therapeutics' Current Deferred Revenue crashed by 7995.17% in 2022, and later crashed by 8192.77% in 2023.
  • Over the past 4 years, Relay Therapeutics' Current Deferred Revenue (Quarter) stood at $248000.0 in 2021, then plummeted by 66.53% to $83000.0 in 2022, then plummeted by 71.08% to $24000.0 in 2023, then surged by 31895.83% to $7.7 million in 2024.
  • Its Current Deferred Revenue stands at $7.7 million for Q4 2024, versus $24000.0 for Q3 2023 and $15000.0 for Q2 2023.